All In MedTech

FDA Clearance Tracker · P030017-S363

Spectra WaveWriter SCS System, WaveWriter Alpha SCS System, WaveWriter Alpha Prime SCS System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 5, 2024 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P030017-S363
Device name
Spectra WaveWriter SCS System, WaveWriter Alpha SCS System, WaveWriter Alpha Prime SCS System
Applicant location
Valencia, CA
Received
May 30, 2023
Decided
Feb 5, 2024
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P030017

Device type

Device class
Class III

Every decision under product code LGW

FDA's approval statement

As written in FDA's record.

Approval for the addition of the treatment of chronic intractable low back and leg pain without prior back surgery in the Indications for Use statement for the Spectra WaveWriter SCS System, WaveWriter Alpha SCS System, and WaveWriter Alpha Prime SCS System.

Source documents

Other decisions for Boston Scientific Corp

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.